Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

FULBullishM&Anews

High materiality9/10

HB Fuller to Acquire AMS, Expanding Medical Growth with ~$55m Synergies

Jun 25, 2026, 2:13 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strategic, accretive deal with clear synergy targets and deleveraging plan; potential near-term uplift on deal certainty and cross-selling opportunities.

AI summary

What happened, with direct paths to the underlying reporting

HB Fuller has launched a cash offer for AMS at £2.85 per share, valuing AMS at about £715 million. The deal broadens HB Fuller’s medical adhesives portfolio, adds cross-border distribution, and targets roughly $55 million in run-rate synergies by 2031. It would raise the total addressable market to about $95 billion and aims to deleverage to 2.5–3x within two years after closing.

HB Fuller to acquire AMS for £2.85 per AMS share; EV ~£715m.
Pre-synergy EBITDA multiple 12.9x; post-synergy <8x with run-rate synergies ~$55m.
TAM expands by $15B to $95B; AMS boosts tissue bonding and biosurgicals offerings.
AMS adds European footprint; accelerates HB Fuller US penetration via cross-selling.
Financing is 100% committed; HB Fuller targets 2.5x–3x leverage within two years.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

HB Fuller to Acquire AMS, Expanding Medical Growth with ~$55m Synergies

HB Fuller to acquire AMS for £715 million, expanding medical adhesives portfolio

FUL poised for Q2 earnings with modest beat expectations and dividend rise

H.B. Fuller Unveils Takeover Proposal for Advanced Medical Solutions

JP Morgan Slashes H.B. Fuller Price Forecast For Softening Growth